Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.32 |
| ▸ | FASN | P49327 | 3/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29270781 | 0.84 | TP53 (0.37) | TP53PTGDR2MAPTLMNASMN1; SMN2 | |
| SCHEMBL29270780 | 0.84 | SHMT1 (0.31) | TP53 | |
| SCHEMBL29270791 | 0.84 | TRPM8 (0.34) | TP53MAPTLMNASMN1; SMN2NPC1 | |
| SCHEMBL29270696 | 0.84 | TP53 (0.32) | TP53MAPTLMNASMN1; SMN2NPC1 | |
| SCHEMBL29270695 | 0.84 | HDAC6 (0.34) | TP53PTGDR2MAPTLMNA | |
| SCHEMBL29270759 | 0.83 | TP53 (0.32) | TP53MAPTLMNASMN1; SMN2NPC1 | |
| SCHEMBL29270692 | 0.82 | AGTR1 (0.36) | TP53 | |
| SCHEMBL26961990 | 0.82 | POLB (0.34) | TP53MAPK9MAPTSMN1; SMN2NPC1 | |
| SCHEMBL29270744 | 0.81 | TP53 (0.34) | TP53MAPTLMNASMN1; SMN2 | |
| SCHEMBL29270810 | 0.81 | TP53 (0.35) | TP53MAPTLMNASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116964048-A | Bicyclic tetrahydroazepine derivatives for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2023-10-27 | — | — | CN | disclosed |